Novo Ventures, the ventures arm of Novo Holdings, is pleased to note the $ 94 million Initial Public Offering on NASDAQ of its portfolio company Reneo Pharmaceuticals [RPHM]. Reneo Pharmaceuticals is a US-based clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases. Reneo is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes. REN001 has been shown to increase transcription of genes involved in mitochondrial function and increase fatty acid oxidation, and may increase production of new mitochondria.
Learn more at https://reneopharma.com/.